Neue Antikoagulantien – Gleichwertig oder wirksamer, gleich oder besser verträglich?
Autor: | Job Harenberg |
---|---|
Rok vydání: | 2009 |
Předmět: | |
Zdroj: | Der Klinikarzt. 38:443-451 |
ISSN: | 1439-3859 0341-2350 |
Popis: | Initial clinical trials have shown that new oral anticoagulants yield at least equal or even more effective and at least equally or better tolerated results than INR-adjusted coumarins. So far, data have been published for Dabigatran for atrial fibrillation. Further results for Rivaroxaban and Apixaban for this will be shortly available. Initial data for the systemically applied new anticoagulants show an improved efficacy of the intravenously applied direct factor Xa inhibitor Otamixaban in patients with unstable angina pectoris. The very long-acting subcutaneously administered Idrabiotaparinux is being tried out on pulmonary embolism patients. The neutralisation of the anticoagulant effect and the elimination of the substance by means of intravenously administered Avidin (an ovalbumin) are important. |
Databáze: | OpenAIRE |
Externí odkaz: |